MoxDuo IR: Phase III started

QRxPharma began the double-blind, U.S. Phase III Study 009 trial in 140 patients. The trial will evaluate a flexible regimen of MoxDuo IR starting at 12 mg morphine/8 mg oxycodone vs. a fixed regimen ...